EsoCap AG announced today that the South Africa Patent and Trademark Office has issued the Patent No. 2017/03831 on March 28th, 2018 which is directed at the smart application technology enabling specific site-directed treatments of several diseases of the esophagus.
EsoCap AG is pursuing similar patent applications in other regions and countries including the USA, Europe, Japan as well as further strategic countries.
“The issuance of the South African patent confirms the novelty of the EsoCap technology” commented Isabelle Racamier, CEO of EsoCap AG. “We are committed to rapidly develop the EsoCap technology that may be beneficial in at least six therapeutic indications affecting 370 mio patients.”
Under a worldwide agreement, the University of Greifswald in Germany has granted EsoCap the exclusive rights for this unique drug delivery technology developed by the University of Greifswald. Up to now the local treatment of diseases of the esophagus was not possible due to the ultra-short transit time of conventional drug formulations. “The EsoCap smart application technology is definitely a paradigm shift for the effective and safe treatment of esophagus diseases” said Dr. Peter Stangier, Director Strategic Planning of EsoCap AG.
